Wednesday, February 07, 2024
Halia Therapeutics, a company specializing in neuroinflammation-targeting drugs, and Canary Speech, a leader in artificial intelligence vocal biomarker technology, have announced a collaboration to transform the monitoring and treatment of Alzheimer's disease.
This partnership utilizes Canary Speech's AI vocal biomarker platform, which analyzes subtle voice pattern changes to monitor cognitive function in Alzheimer's patients. This method offers a non-invasive way to track disease progression and treatment effectiveness. Halia will use these insights to enhance the development of its Alzheimer's drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2). By focusing on this component, Halia aims to slow or halt disease progression.
Halia Therapeutics, said, "This collaboration is a significant step in addressing Alzheimer's disease challenges and advancing HT-4253's clinical development."
Henry O'Connell, CEO of Canary Speech, stated, "We are excited to combine our AI technology with Halia's drug development expertise to improve Alzheimer's patient care."
Canary Speech is a leader in speech digital biomarkers, providing real-time vocal analysis for health and pharmaceutical applications. HT-4253 is an orally administered small molecule targeting LRRK2, with plans for a phase 1 clinical trial by 2024.